Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRBP Corbus Pharmaceuticals

Post-Mkt 09-04 16:30:52 EDT

11.08

-0.38

-3.32%

盘后11.08

+0.000.00%

16:10 EDT

High11.45	Low11.06	Vol222.47K
Open11.37	D1 Closing11.46	Amplitude3.40%
Mkt Cap214.30M	Tradable Cap192.97M	Total Shares19.34M
T/O2.50M	T/O Rate1.28%	Tradable Shares17.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals","latestPrice":11.08,"timestamp":1788552000000,"preClose":11.46,"halted":0,"volume":222466,"hourTrading":{"tag":"盘后","latestPrice":11.08,"preClose":11.08,"latestTime":"16:10 EDT","volume":1703,"amount":18869.24,"timestamp":1788552604739,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03315881326352537,"floatShares":17416483,"shares":19341300,"eps":-6.088859,"marketStatus":"Post-Mkt","change":-0.38,"latestTime":"09-04 16:30:52 EDT","open":11.37,"high":11.445,"low":11.055,"amount":2497895,"amplitude":0.034031,"askPrice":11.08,"askSize":50,"bidPrice":10.06,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.088859,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788566400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":11.46,"preHourTrading":{"tag":"盘前","latestPrice":11.35,"preClose":11.46,"latestTime":"09:22 EDT","volume":4033,"amount":45898.794631000004,"timestamp":1788528155596,"change":-0.11,"changeRate":-0.009599,"amplitude":0.020942},"postHourTrading":{"tag":"盘后","latestPrice":11.08,"preClose":11.08,"latestTime":"16:10 EDT","volume":1703,"amount":18869.24,"timestamp":1788552604739,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.358931,"impliedVol":1.7766,"impliedVolPercentile":0.881},"requestUrl":"/m/hq/s/CRBP","defaultTab":"news","newsList":[{"id":"2664844880","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844880","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844880?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:19","pubTimestamp":1788383940,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 1.77% to $11.48 Wednesday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index  rising 0.45% to 26,217.83 and the Dow Jones Industrial Average  rising 0.56% to 53,061.95.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 44.16% below its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  rose 2.03% to $5.53, Fortress Biotech Inc.  rose 1.87% to $2.73, and Viking Therapeutics Inc.  fell 0.50% to $33.50.Data source: Dow Jones Market Data, FactSet. Data compiled September 2, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664619938","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2664619938","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664619938?lang=en_us&edition=fundamental","pubTime":"2026-09-02 05:18","pubTimestamp":1788297480,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 3.39% to $11.28 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 1.03% to 26,099.77 and Dow Jones Industrial Average  falling 0.79% to 52,766.88.Corbus Pharmaceuticals Holdings Inc. closed 45.14% short of its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 0.37% to $5.42, Fortress Biotech Inc.  fell 2.01% to $2.68, and Viking Therapeutics Inc.  rose 2.72% to $33.67.Trading volume  eclipsed its 50-day average volume of 433,524.Data source: Dow Jones Market Data, FactSet. Data compiled September 1, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203543","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203543?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:21","pubTimestamp":1787865660,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 1.50% to $11.13 Thursday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index  rising 1.57% to 26,541.35 and the Dow Jones Industrial Average  rising 0.20% to 53,569.44.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 45.87% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  rose 1.68% to $5.44, Fortress Biotech Inc.  fell 0.36% to $2.80, and Viking Therapeutics Inc.  fell 1.51% to $33.86.Data source: Dow Jones Market Data, FactSet. Data compiled August 27, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757361","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757361","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662757361?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:20","pubTimestamp":1787692800,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 5.80% to $11.31 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index  rising 0.66% to 26,151.30 and the Dow Jones Industrial Average  rising 0.30% to 53,577.40.This was the stock's third consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 44.99% below its 52-week high of $20.56, which the company achieved on October 20th.The stock outperformed some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 2.06% to $5.44, Fortress Biotech Inc.  fell 3.41% to $2.83, and Viking Therapeutics Inc.  rose 2.83% to $34.17.Trading volume  eclipsed its 50-day average volume of 411,768.Data source: Dow Jones Market Data, FactSet. Data compiled August 25, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662209420","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2662209420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662209420?lang=en_us&edition=fundamental","pubTime":"2026-08-25 05:19","pubTimestamp":1787606340,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 2.99% to $10.69 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 0.26% to 53,417.16 and the NASDAQ Composite Index  falling 0.76% to 25,980.19.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 48.01% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock outperformed some of its competitors Monday, as Vanda Pharmaceuticals Inc.  rose 0.95% to $5.33, Fortress Biotech Inc.  rose 2.09% to $2.93, and Viking Therapeutics Inc.  fell 1.95% to $33.23.Trading volume  eclipsed its 50-day average volume of 392,679.Data source: Dow Jones Market Data, FactSet. Data compiled August 24, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661237755","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2661237755","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661237755?lang=en_us&edition=fundamental","pubTime":"2026-08-21 05:32","pubTimestamp":1787261520,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slipped 1.50% to $9.84 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 1.00% to 26,067.17 and Dow Jones Industrial Average  falling 1.32% to 52,759.21.This was the stock's third consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 52.14% below its 52-week high of $20.56, which the company reached on October 20th.Despite its losses, the stock outperformed some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  fell 3.41% to $5.38, Fortress Biotech Inc.  fell 2.81% to $2.77, and Viking Therapeutics Inc.  fell 4.50% to $34.36.Trading volume  remained 85,468 below its 50-day average volume of 385,823.Data source: Dow Jones Market Data, FactSet. Dat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661236972","title":"CRBP’s CRB-701 Phase 3 Trial Sets the Stage for a Key Oncology Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2661236972","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661236972?lang=en_us&edition=fundamental","pubTime":"2026-08-21 00:32","pubTimestamp":1787243528,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings ($CRBP) announced an update on their ongoing clinical study. Corbus Pharmaceuticals Inc. is launching a Phase 3 stu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crbps-crb-701-phase-3-trial-sets-the-stage-for-a-key-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crbps-crb-701-phase-3-trial-sets-the-stage-for-a-key-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660975464","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660975464","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660975464?lang=en_us&edition=fundamental","pubTime":"2026-08-19 05:21","pubTimestamp":1787088060,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 3.91% to $10.08 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 1.33% to 26,289.71 and Dow Jones Industrial Average  falling 0.22% to 53,343.40.The stock's fall snapped a five-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 50.97% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc.  rose 3.42% to $5.44, Fortress Biotech Inc.  rose 3.19% to $2.91, and Viking Therapeutics Inc.  fell 0.77% to $33.37.Trading volume  remained 54,139 below its 50-day average volume of 383,255.Data source: Dow Jones Market Data, FactSet. Data c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432955","title":"Corbus Pharmaceuticals Holdings Inc. Stock Rises 4.0%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432955?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:35","pubTimestamp":1786998900,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. rose 4.0% to $10.49 on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 0.3% to 26,644.91 and Dow Jones Industrial Average falling 0.5% to 53,459.78.This was the stock's fifth consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 49.0% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock outperformed some of its peers, as Vanda Pharmaceuticals Inc. rose 0.8% to $5.26, Fortress Biotech Inc. fell 3.8% to $2.82, and Viking Therapeutics Inc. rose 1.33% to $33.63.Trading volume totaled 869,122, compared to the 50-day average of 382,460.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660543363","title":"Corbus Grants CMO Inducement Awards Including Option for 191,676 Shares at $10.09 Exercise Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2660543363","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660543363?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:00","pubTimestamp":1786975240,"startTime":"0","endTime":"0","summary":"Corbus grants CMO inducement awards including option for 191,676 shares at $10.09 exercise priceCorbus granted inducement equity awards to Chief Medical Officer Leonardo Nicacio effective Aug. 16, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLGMWQm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4585","NDAQ","IE00BN0W2T93.GBP","BK4588","SG9999014039.USD","CRBP","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","SG9999014013.SGD","LU0314104364.USD","BCDF","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660508433","title":"Corbus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660508433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660508433?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:00","pubTimestamp":1786975201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA7ZWGJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332014","title":"Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332014","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332014?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:00","pubTimestamp":1786975200,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., Aug.  17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346190/0/en/corbus-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","LCLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660488427","title":"Corbus Pharmaceuticals price target lowered to $33 from $34 at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2660488427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660488427?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:03","pubTimestamp":1786953781,"startTime":"0","endTime":"0","summary":"Mizuho lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $33 from $34 and keeps an Outperform rating on the shares. The firm upda...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-price-target-lowered-to-33-from-34-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-price-target-lowered-to-33-from-34-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659130694","title":"Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659130694","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659130694?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:22","pubTimestamp":1786612960,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings (CRBP) has an average rating of buy and mean price target of $34.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659183427","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2659183427","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659183427?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:21","pubTimestamp":1786569660,"startTime":"0","endTime":"0","summary":"DJ Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily GainsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rose 2.63% to $9.76 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index  rising 0.54% to 26,588.49 and the Dow Jones Industrial Average  falling 0.04% to 53,770.27.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 52.53% below its 52-week high of $20.56, which the company achieved on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Vanda Pharmaceuticals Inc.  rose 5.27% to $5.19, Fortress Biotech Inc.  rose 5.36% to $2.75, and Viking Therapeutics Inc.  rose 0.65% to $34.02.Data source: Dow Jones Market Data, FactSet. Data compiled August 12, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659297183","title":"Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659297183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659297183?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:10","pubTimestamp":1786569008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA) and Corbus Pharmaceutica...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aura-biosciences-inc-aura-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aura-biosciences-inc-aura-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRBP","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188855","title":"Corbus Chief Business Officer Nishant Saxena Acquires 2,600 Shares Worth $25,037.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188855","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188855?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:31","pubTimestamp":1786566678,"startTime":"0","endTime":"0","summary":"Corbus Chief Business Officer Nishant Saxena acquires 2,600 shares worth $25,037.44Corbus Pharmaceuticals Chief Business Officer Nishant C. Saxena bought 2,600 common shares at USD 9.63 each.Beneficia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLccjC59:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corbus Chief Business Officer Nishant Saxena Acquires 2,600 Shares Worth $25,037.44","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658896974","title":"RBC Capital Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658896974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658896974?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:06","pubTimestamp":1786532804,"startTime":"0","endTime":"0","summary":"In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals, with a price target of $36.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-their-buy-rating-for-corbus-pharmaceuticals-crbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658607951","title":"Corbus Pharma CFO Sean Moran Sells 12,000 Shares for $120,971","url":"https://stock-news.laohu8.com/highlight/detail?id=2658607951","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658607951?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:33","pubTimestamp":1786393982,"startTime":"0","endTime":"0","summary":"Corbus Pharma CFO Sean Moran sells 12,000 shares for $120,971Corbus Pharmaceuticals CFO Sean F. Moran sold 12,000 common shares on Aug. 7, 2026 at a weighted average price of USD 10.08.Directly held s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL5pJJyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corbus Pharma CFO Sean Moran Sells 12,000 Shares for $120,971","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936951","title":"Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.0%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936951","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936951?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:32","pubTimestamp":1786393920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slid 7.0% to $9.46 on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 0.3% to 26,605.36 and Dow Jones Industrial Average falling 0.1% to 53,975.98.The stock's fall snapped a four-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 54.0% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 0.4% to $5.02, Fortress Biotech Inc. rose 3.0% to $2.75, and Viking Therapeutics Inc. rose 0.53% to $34.44.Trading volume totaled 335,566, compared to the 50-day average of 412,692.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":0.0296},{"period":"1month","weight":0.2191},{"period":"3month","weight":0.5159},{"period":"6month","weight":0.4307},{"period":"1year","weight":0.1635},{"period":"ytd","weight":0.4079}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.197993},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046477},{"month":5,"riseRate":0.583333,"avgChangeRate":0.055971},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.044414},{"month":7,"riseRate":0.25,"avgChangeRate":-0.049826},{"month":8,"riseRate":0.666667,"avgChangeRate":0.105723},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.075047},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corbus Pharmaceuticals,CRBP,Corbus Pharmaceuticals股票,Corbus Pharmaceuticals股票老虎,Corbus Pharmaceuticals股票老虎国际,Corbus Pharmaceuticals行情,Corbus Pharmaceuticals股票行情,Corbus Pharmaceuticals股价,Corbus Pharmaceuticals股市,Corbus Pharmaceuticals股票价格,Corbus Pharmaceuticals股票交易,Corbus Pharmaceuticals股票购买,Corbus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}